Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

Aug 26, 2023   |  Anthony A. Bavry, MD,MPH,FACC

Clinical Trial

The goal of the DAPA-HF trial was to evaluate dapagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor) compared with placebo among patients with heart failure with reduced ejection fraction (HFrEF).

Clinical Topics: Anticoagulation Management, Dyslipidemia, Heart Failure and Cardiomyopathies, Lipid Metabolism, Statins, Acute Heart Failure, Heart Failure and Cardiac Biomarkers

Keywords: AHA Annual Scientific Sessions, AHA21, AHA19, ACC Annual Scientific Session, acc20, Endothelin-1, ESC Congress, ESC23, ESC21, ESC 19, Benzhydryl Compounds, Glomerular Filtration Rate, Glucosides, Heart Failure, Hospitalization, Hypotension, Natriuretic Peptide, Brain, Peptide Fragments, Renal Insufficiency, Sodium-Glucose Transporter 2, Stroke Volume, Diabetes Mellitus, Diuretics, Furosemide, Troponin